# AngioDynamics, Inc. (ANGO): A Healthcare Innovator with Notable 70% Upside Potential

- Link: https://www.directorstalkinterviews.com/angiodynamics-inc-ango-a-healthcare-innovator-with-notable-70-upside-potential/4121215123
- Published: 2025-09-05T10:33:59+01:00
- Author: Madison Wilson

For investors with an eye on the healthcare sector, AngioDynamics, Inc. (NASDAQ:
ANGO) presents a compelling opportunity. The Latham, New York-based medical technology
company is carving out a niche in the competitive medical instruments and supplies
industry. Despite its current challenges reflected in certain financial metrics,
the company’s innovative approach and analyst endorsement suggest significant upside
potential.

AngioDynamics specializes in designing, manufacturing, and selling medical devices
for treating peripheral vascular disease, oncology, and surgical conditions. Among
its diverse portfolio, the Auryon Atherectomy system and the AlphaVac mechanical
thrombectomy system stand out, showcasing the company’s commitment to advanced medical
technologies. These products demonstrate AngioDynamics’ focus on innovation, positioning
it as a key player in the healthcare sector.

Currently, AngioDynamics’ stock trades at $10.73, comfortably nestled within its
52-week range of $5.88 to $12.94. While the stock’s price movement has been modest,
with a slight 0.01% increase recently, it’s the projected growth that catches the
eye. Analysts have set a target price range of $16.00 to $24.00, with an average
target of $18.25, representing a potential upside of 70.08%. This optimistic outlook
is backed by three buy ratings, underscoring strong analyst confidence in the company’s
future growth prospects.

Despite the promising future, the financial metrics reveal areas of concern. The
company’s trailing P/E ratio is not available, and its forward P/E stands at a daunting-
119.22, indicating negative earnings expectations in the near term. Furthermore,
AngioDynamics reports a negative EPS of -0.83 and a concerning return on equity 
of -17.50%. The free cash flow also stands at a negative $3,501,750, reflecting 
challenges in generating cash from operations.

However, revenue growth offers a silver lining, with a reported increase of 12.90%.
This growth, coupled with the company’s innovative product line, suggests AngioDynamics
is on a path to potentially overcoming its current profitability issues. The technical
indicators add another layer of intrigue, with the stock trading above its 50-day
and 200-day moving averages, hinting at positive momentum.

Dividend-seeking investors might look elsewhere, as AngioDynamics does not currently
offer a dividend yield, maintaining a payout ratio of 0.00%. For those focused on
capital appreciation rather than income, the company’s strategic market position
and analyst support make it a noteworthy consideration.

In the dynamic landscape of healthcare, AngioDynamics, Inc. stands out for its commitment
to innovation and its potential for significant stock price appreciation. While 
the financial challenges are apparent, the company’s strategic initiatives and analyst
endorsements suggest that it might be on the cusp of a turnaround. For investors
willing to bet on innovation driving future growth, AngioDynamics offers a fascinating
opportunity.

Share on: